Citations Appearing in 2004

  1. Anderton, M.J., M.M. Manson, R. Verschoyle, A. Gescher, W.P. Steward, M.L. Williams and D.E. Mager. Physiological modeling of formulated and crystalline 3,3′-diindolylmethane pharmacokinetics following oral administration in mice. Drug Metab. Dispos. 32(6):632-638, 2004.
  2. Baker, S.D., M. Zhao, C.K.K. Lee, J. Verweij, Y. Zabelina, J.R. Brahmer, A.C. Wolff, A. Sparreboom and M.A. Carducci. Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Clinical Cancer Research 10(6):1976-1983, 2004.
  3. Bates, S.E., S. Bakke, M. Kang, R.W. Robey, S.P. Zhai, P. Thambi, C. Chen, S. Patil, T. Smith, S.M. Steinberg, M. Merino, B. Goldspiel, B. Meadows, W.D. Stein, P. Choyke, F. Balis, W.D. Figg and T. Fojo. A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma. Clinical Cancer Research 10(14):4724-4733, 2004.
  4. Bhasi, K., L. Zhang, A.D. Zhang and M. Ramanathan. Analysis of pharmacokinetics, pharmacodynamics, and pharmacogenomics data sets using VizStruct, a novel multidimensional visualization technique. Pharmaceutical Research 21(5):777-780, 2004.
  5. Berg, S.L., A. Aleksic, L. McGuffey, R. Dauser, J. Nuchtern, B. Bernacky and S.M. Blaney. Plasma and cerebrospinal fluid pharmacokinetics of rebeccamycin (NSC 655649) in nonhuman primates. Cancer Chemotherapy and Pharmacology 54(2):127-130, 2004.
  6. Berg, S.L., J. Stone, J.J. Xiao, K.K. Chan, J. Nuchtern, R. Dauser, L. McGuffey, P. Thompson and S.M. Blaney. Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates. Cancer Chemotherapy and Pharmacology 54(1):85-88, 2004.
  7. Bondareva, I.B., R.W. Jelliffe, A.V. Sokolov and I.F. Tischenkova. Nonparametric population modeling of valproate pharmacokinetics in epileptic patients using routine serum monitoring data: implications for dosage. Journal of Clinical Pharmacy Therapeutics 29(2):105-120, 2004.
  8. Bos, A.M.E., K. Boom, A.A. Vinks, H.M. Boezen, J. Wanders, P. Dombernovsky, S. Aamdal, E.G.E. de Vries and D.R.A. Uges. Development of an optimal sampling strategy for clinical pharmacokinetic studies of the novel anthracycline disaccharide analogue MEN-10755. Cancer Chemotherapy and Pharmacology 54(1):64-70, 2004.
  9. Chintagumpala, M., S.M. Blaney, L.R. Bomgaars, A. Aleksic, J.F. Kuttesch, R.A. Klenke and S.L. Berg. Phase I and pharmacokinetic study of thalidomide with carboplatin in children with cancer. Journal of Clinical Oncology 22(21):4394-4400, 2004.
  10. Chow, W.A., T.W. Synold, M.L. Tetef, J. Longmate, P. Frankel, J. Lawrence, Z. Al-Khadimi, L. Leong, D. Lim, K. Margolin, R.J. Morgan Jr., J. Raschko, S. Shibata, G. Somlo, P. Twardowski, Y. Yen and J.H. Doroshow. Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies. Cancer Chemotherapy and Pharmacology 54(3):241-248, 2004.
  11. Clardy, D.O. Population pharmacokinetics of ethanol in drinking drivers using breath measures. Therapeutic Drug Monitoring 26(4):391-400, 2004.
  12. de Lima, M., D. Couriel, P.F. Thall, X.M. Wang, T. Madden, R. Jones, E.J. Shpall, M. Shahjahan, B. Pierre, S. Giralt, M. Korbling, J.A. Russell, R.E. Champlin and B.S. Andersson. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 104(3):857-864, 2004.
  13. Daw, N.C., W. L. Furman, C. F. Stewart, L. C. Iacono, M. Krailo, M. Bernstein, J. E. Dancey, S. Blaney and P. C. Adamson . AA phase I trial and pharmacokinetic study of gefitinib in pediatric patients with refractory solid tumors: A Children’s Oncology Group Study. Journal of Clinical Oncology 22(14S):8522, 2004.
  14. Di Marco, M.P., J. Chen, I.W. Wainer, and M.P. Ducharme. A population pharmacokinetic-metabolism model for individualizing ciprofloxacin therapy in ophthalmology. Therapeutic Drug Monitoring 26(4):401-407, 2004.
  15. Drusano, G.L., S.L. Preston, C. Fowler, M. Corrado, B. Weisinger and J. Kahn. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. Journal of Infectious Diseases 189(9):1590-1597, 2004.
  16. Fetterly, G.J. and R.M. Straubinger. Pharmacokinetics of paclitaxel-containing liposomes in rats. AAPS PharmSciTech 5(4):32, 2004.
  17. Fisher, J.W., J.A. Florian, R.S. Parker, A.P. Venook, M.J. Ratain and M.J. Egorin. Evaluation of potentially excessive plasma gemcitabine (dFdC) concentrations produced by 30-minute dFdC infusions. Journal of Clinical Oncology 22(14S ):2019, 2004.
  18. Freeman, B.B., L.C. Iacono, P.S. Hinds, B.I. Razzouk and C.F. Stewart. Pharmacokinetics (PK) of intravenously (IV) administered epoetin alfa in pediatric patients receiving myelosuppressive chemotherapy. Journal of Clinical Oncology 22(14S):8552, 2004.
  19. Gumbo, T., A. Louie, M.R. Deziel, L.M. Parsons, M. Salfinger and G.L. Drusano. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. Journal of Infectious Diseases 190(9):1642-1651, 2004
  20. Han, Y.S., H.M. Shen, B.I. Carr, P. Wipf, J.S. Lazo and S.S. Pan. NAD(P)H : Quinone oxidoreductase-1-dependent and -independent cytotoxicity of potent quinone Cdc25 phosphatase inhibitors. Journal of Pharmacology and Experimental Therapeutics 309(1):64-70, 2004.
  21. Holleran, J.L., J. Fourcade, M.J. Egorin, J.L. Eiseman, R.A. Parise, S.M. Musser, K.D. White, J.M. Covey, G.L. Forrest and S.S. Pan. In vitro metabolism of the phosphatidylinositol 3-kinase inhibitor, wortmannin, by carbonyl reductase. Drug Metabolism and Disposition 32(5):490-496, 2004.
  22. Iacono, L.C., D. Adams, A.C. Homans, A. Guillot, J.S. McCune and C.F. Stewart. Topotecan disposition in an anephric child. Journal of Pediatric Hematology Oncology 26(9):596-600, 2004.
  23. Jin, F. and W. Krzyzanski. Pharmacokinetic model of target-mediated disposition of thrombopoietin. AAPS PharmSciTech 6(1), 2004.
  24. Jin, J.Y., D.C. DuBois, R.R. Almon and W.J. Jusko. Receptor/gene-mediated pharmacodynamic effects of methylprednisolone on phosphoenolpyruvate carboxykinase regulation in rat liver. Journal of Pharmacology and Experimental Therapeutics 309(1):328-339, 2004.
  25. Johansen, M., T. Zukowski, P.M. Hoff, R.A. Newman, D. Ni, T. Hutto, J. Abbruzzeese, E. Berghorn, F. Hausheer and T. Madden. Final results of a phase I and pharmacokinetic study of gamma-methylene-10-deazaaminopterin (MDAM) administered intravenously daily for five consecutive days in patients with solid tumors. Cancer Chemotherapy and Pharmacology 53(5):370-376, 2004.
  26. Jung, L.L., R.K. Ramanathan, M.J. Egorin, R.Z. Jin, C.P. Belani, D.M. Potter, S. Strychor, D.L. Trump, C. Walko, M. Fakih and W.C. Zamboni. Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors. Cancer Chemotherapy and Pharmacology 54(6):487-496, 2004.
  27. Kamal, M.A. and W.J. Jusko. Interactions of prednisolone and other Immunosuppressants used in dual treatment of systemic lupus erythematosus in lymphocyte proliferation assays. Journal of Clinical Pharmacology 44(9):1034-1045, 2004.
  28. Kang, D.W., J.B. Schwartz and D. Verotta. A sample size computation method for non-linear mixed effects models with applications to pharmacokinetics models.Statistics in Medicine 23(16):2551-2566, 2004.
  29. Kellie, S.J., P. Koopmans, J. Earl, C. Nath, D. Roebuck, D.R.A. Uges and S.S.N. de Graaf. Increasing the dosage of vincristine. Cancer 100(12):2637-2643, 2004.
  30. Le, L.H., C. Erlichman, L. Pillon, J.J. Thiessen, A. Day, N. Wainman, E.A. Eisenhauer and M.J. Moore. Phase I and pharmacokinetic study of fostriecin given as an intravenous bolus daily for five consecutive days. Investigational New Drugs 22(2):159-167, 2004.
  31. Mager, D.E., D.R. Abernethy, J.M. Egan and D. Elahi. Exendin-4 pharmacodynamics: Insights from the hyperglycemic clamp technique. Journal of Pharmacology and Experimental Therapeutics 311(2):830-835, 2004.
  32. Meagher, A.K., A. Forrest, A. Dalhoff, H. Stass and J.J. Schentag. Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin. Antimicrobial Agents and Chemotherapy 48(6):2061-2068, 2004.
  33. Moise-Broder, P.A., A. Forrest, M.C. Birmingham and J.J. Schentag. Pharmacodynamics of vancomycin and other antimicrobials in patients with staphylococcus aureus lower respiratory tract infections. Clinical Pharmacokinetics 43(13):925-942, 2004.
  34. Morgan, R.J., T.W. Synold, D. Gandara, F. Muggia, S. Scudder, E. Reed, K. Margolin, J. Raschko, L. Leong, S. Shibata, M. Tetef, S. Vasilev, K. McGonigle, J. Longmate, Y. Yen, W. Chow, G. Somlo, M. Carroll and Doroshow. Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer. Cancer Chemotherapy and Pharmacology 54(4):283-289, 2004.
  35. Okutomi, T., M. Saito, Y. Matsumoto, M. Shimizu, M. Fukuoka and S. Hoka. Altered bupivacaine pharmacokinetics by MgSO4 in rats. Canadian Journal of Anesthesia-Journal Canadien D Anesthesie 51(1):93-94, 2004.
  36. Olafsen, T., G.J. Tan, C.W. Cheung, P.J. Yazaki, J.M. Park, J.E. Shively, L.E. Williams, A.A. Raubitschek, M.F. Press and A.M. Wu. Characterization of engineered anti-pI85(HER-2) (scFv-C(H)3)(2) antibody fragments (minibodies) for tumor targeting. Protein Engineering Design and Selection 17(4):315-323, 2004.
  37. Overholser, B.R., M.B. Kays, A. Forrest and K.M. Sowinski. Sex-related differences in the pharmacokinetics of oral ciprofloxacin. Journal of Clinical Pharmacology 44(9):1012-1022, 2004.
  38. Pauley, J.L., J.C. Panetta, J. Schmidt, N. Nornegay, M.V. Relling and C.H. Pui. Late-onset delayed excretion of methotrexate. Cancer Chemotherapy and Pharmacology 54(2):146-152, 2004.
  39. Ralph, L.D., A.H. Thomson, N.A. Dobbs and C. Twelves. Maximum a posteriori Bayesian estimation of epirubicin clearance by limited sampling. British Journal of Clinical Pharmacology 57(6):764-772, 2004.
  40. Ramakrishnan, R., W.K. Cheung, M.C. Wacholtz, N. Minton and W.J. Jusko. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers. Journal of Clinical Pharmacology 44(9):991-1002, 2004.
  41. Reed, R.C. and S. Dutta. Predicted serum valproic acid concentrations in patients missing and replacing a dose of extended-release divalproex sodium. American Journal of Health-System Pharmacy 61(21):2284-2289, 2004.
  42. Rudek, M.A., R.C. Donehower, P. Statkevich, V.K. Batra, D.L. Cutler and S.D. Baker. Temozolomide in patients with advanced cancer: Phase I and pharmacokinetic study. Pharmacotherapy 24(1):16-25, 2004.
  43. Rudek, M.A., A. Sparreboom, E.S. Garrett-Mayer, D.K. Armstrong, A.C. Wolff, J. Verweij and S.D. Baker. Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. European Journal of Cancer 40(8):1170-1178, 2004.
  44. Samtani, M.N., M. Schwab, P.W. Nathanielsz and W.J. Jusko. Area/moment and compartmental modeling of pharmacokinetics during pregnancy: applications to maternal/fetal exposures to corticosteroids in sheep and rats. Pharmaceutical Research 21(12):2279-2292, 2004.
  45. Samtani, M.N., M. Schwab, P.W. Nathanielsz and W.J. Jusko. Stabilization and HPLC analysis of betamethasone sodium phosphate in plasma. Journal of Pharmaceutical Science 93(3):726-732, 2004.
  46. Satchi-Fainaro, R., M. Puder, J.W. Davies, H.T. Tran, D.A. Sampson, A.K. Greene, G. Corfas and J. Folkman. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nature Medicine 10(3):255-261, 2004.
  47. Segrave, A.M., D.E. Mager, S.A. Charman, G.A. Edwards and C.J.H. Porter. Pharmacokinetics of recombinant human leukemia inhibitory factor in sheep. Journal of Pharmacology and Experimental Therapeutics 309(3):1085-1092, 2004.
  48. Seligman, P.A., N.V. Dahl, J. Strobos, H.C. Kimko, R.B. Schleicher, M. Jones and M.R. Ducharme. Single-dose pharmacokinetics of sodium ferric gluconate complex in iron-deficient subjects. Pharmacotherapy 24(5):574-583, 2004.
  49. Sevcik, C., G. D’Suze, P. Diaz, V. Salazar, C. Hidalgo, H. Azpurua and N. Bracho. Modelling Tityus scorpion venom and antivenom pharmacokinetics. Evidence of active immunoglobulin G’s F(ab ‘)(2) extrusion mechanism from blood to tissues. Toxicon 44(7):731-741, 2004.
  50. Sood, A.K., R. Lush, J.P. Geisler, M.S. Shahin, L. Sanders, D. Sullivan, R.E. Buller and J.I. Sorosky. Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: Results of a phase II trial. Clinical Cancer Research 10(18):6080-6085, 2004.
  51. Sparreboom, A., H. Chen, M.R. Acharya, A.M. Senderowicz, R.A. Messmann, T. Kuwabara, D.J. Venzon, A.J. Murgo, D. Headlee, E.A. Sausville and W.D. Figg. Effects of alpha1-acid glycoprotein on the clinical pharmacokinetics of 7-hydroxystaurosporine. Clinical Cancer Research 10(20):6840-6846, 2004.
  52. Stepensky, D., M. Chorny, Z. Dabour and I. Schumacher. Long-term stability study of L-adrenaline injections: Kinetics of sulfonation and racemization pathways of drug degradation. Journal of Pharmaceutical Sciences 93(4):969-980, 2004.
  53. Stewart, C.F., L.C. Iacono, M. Chintagumpala, S. Kellie, D. Ashley, W.C. Zamboni, M.N. Kirstein, M. Fouladi, L.G. Seele, D. Wallace, P.J. Houghton and A. Gajjar. Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. Journal of Clinical Oncology 22(16):3357-3365, 2004.
  54. Suarez-Kurtz, G., R.D.C. Estrela and M.C. Salvadori. Prednisolone – Limited sampling strategies for estimating pharmacokinetic parameters. Therapeutic Drug Monitoring 26(1):16-22, 2004
  55. Turner, P.K., J.A. Houghton, I. Petak, D.M. Tillman, L. Douglas, L. Schwartzberg, C.A. Billups, J.C. Panetta and C.F. Stewart. Interferon-gamma pharmacokinetics and pharmacodynamics in patients with colorectal cancer. Cancer Chemotherapy and Pharmacology 53(3):253-260, 2004.
  56. Tran, H., D. Petropoulos, L. Worth, C.A. Mullen, T. Madden, B. Andersson, M. Choroszy, J. Nguyen, S.K. Webb and K.W. Chan. Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogenic stem cell transplantation. Biology of Blood and Marrow Transplantation 10(11):805-812, 2004.
  57. Verschraegen, C.F., A.P. Kudelka, W. Hu, M. Vincent, J.J. Kavanagh, E. Loyer, L. Bastien, A. Duggal and R. De Jager. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan. Cancer Chemotherapy and Pharmacology 53(1):1-7, 2004.
  58. Wagner, L.M., K.R. Crews, L.C. Iacono, P.J. Houghton, C.E. Fuller, M.B. McCarville, R.E. Goldsby, K. Albritton, C.F. Stewart and V.M. Santana. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clinical Cancer Research 10(3):840-848, 2004.
  59. Watchers, F.M., H.J.M. Groen, J.G. Maring, J.A. Gietema, M. Porro, H. Dumez, E.G.E. de Vries and A.T. van Oosterom. A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours. British Journal of Cancer 90(12):2261-2267, 2004.
  60. Weiss, M. and W.K. Kang. Inotropic effect of digoxin in humans: Mechanistic pharmacokinetic/pharmacodynamic model based on slow receptor binding. Pharmaceutical Research 21(2):231-236, 2004.
  61. Weiss, M., M. Baek and W. Kang. Systems analysis of digoxin kinetics and inotropic response in the rat heart: effects of calcium and KB-R7943. American Journal of Physiology-Heart and Circulatory Physiology 287(4):H1857-H1867, 2004.
  62. Wiederhold, N.P., D.P. Kontoyiannis, J. Chi, R.A. Prince, V.H. Tam and R.E. Lewis. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. The Journal of Infectious Diseases 190(8):1464-1471, 2004.
  63. Wong, J.Y.C., D.Z. Chu, L.E. Williams, D.M. Yamauchi, D.N. Ikle, C.S. Kwok, A. Liu, S. Wilczynski, D. Colcher, P.J. Yazaki, J.E. Shively, A.M. Wu and A.A. Raubitschek. Pilot trial evaluating an I-123-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer. Clinical Cancer Research 10(15):5014-5021, 2004.
  64. Wu, J.T., D.H. Kirn and L.M. Wein. Analysis of a three-way race between tumor growth, a replication-competent virus and an immune response. Bulletin of Mathematical Biology 66(4):605-625, 2004.
  65. Yule, S.M., L. Price, A.D. McMahon, A.D.J. Pearson and A.V. Boddy. Cyclophosphamide metabolism in children with non-Hodgkin’s lymphoma. Clinical Cancer Research 10(2):455-460, 2004.
  66. Zamboni, W.C., A.C. Gervais, M.J. Egorin, J.H.M. Schellens, E.G. Zuhowski, D. Pluim, E. Joseph, D.R. Hamburger, P.K. Working, G. Colbern, M.E. Tonda, D.M. Potter and J.L. Eiseman. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077B103) in a preclinical tumor model of melanoma. Cancer Chemotherapy and Pharmacology 53(4):329-336, 2004.
  67. Zamboni, W.C., L.L. Jung, M.J. Egorin, D.M. Potter, D.M. Friedland, C.P. Belani, S.S. Agarwala, M.M.W. Wong, M. Fakih, D.L. Trump, R.Z. Jin, S. Strychor, M. Vozniak, M. Troetschel and R.K. Ramanathan. Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors. Clinical Cancer Research 10(15):5058-5064, 2004.